Vir BiotechnologyVIR
Market Cap: $1.06B
About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Employees: 587
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
38% more call options, than puts
Call options by funds: $2.65M | Put options by funds: $1.92M
30% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 27
4% more funds holding
Funds holding: 205 [Q1] → 213 (+8) [Q2]
6% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 71
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
3.07% less ownership
Funds ownership: 67.78% [Q1] → 64.71% (-3.07%) [Q2]
16% less capital invested
Capital invested by funds: $928M [Q1] → $783M (-$144M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 1,318%upside $110 | Buy Reiterated | 20 Aug 2024 |
Barclays Gena Wang 42% 1-year accuracy 10 / 24 met price target | 261%upside $28 | Overweight Maintained | 2 Aug 2024 |